Topics:

Cervical Cancer

New HPV Vaccine Could Prevent 90% of Cervical Cancers

A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.

Cervical Cancer

A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.

Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.

Urine tests effectively screen for HPV, but more data is needed to determine whether they can correctly diagnose cervical disease.

The US Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of patients with recurrent or metastatic cervical cancer.

In light of the recent FDA approval of HPV testing for women as a screening method for cervical cancer, we discuss changing guidelines with two experts.

The highest rates of cervical cancer occur in women aged 65 to 69, according to new estimates. This suggests that screening guidelines may need to be reconsidered.

The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.

Pages

Subscribe to Cervical Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.